International Gemmological Institute (India) Ltd

- No specific information or announcements were made regarding any current or future fundraising through debt or equity during the call. - The company is currently sitting on a strong cash position with approximately INR 400 crores in cash reserves. - Management mentioned keeping an eye open for opportunities such as acquisitions but has no specific plans or information to share about raising funds at this time. - Dividends are part of the plan to utilize surplus cash, but no new fundraising initiatives were discussed.

- The company is expanding its capacity, leading to increased fixed assets and consequent higher depreciation and amortization expenses. - There is a focus on ramping up capacity in other locations such as Dubai, Hong Kong, and Turkey to leverage any supply chain shifts due to tariffs or market dynamics. - The management is actively scouting for opportunities to expand their lab presence in fast-growing markets, with recent expansions including an additional lab in Dubai and two labs in China. - No specific or announced strategic acquisitions or investments at the moment, but the company is keeping its eyes open for potential acquisition opportunities given the strong cash position (~INR 400 crores). - Some of the cash reserves may also be utilized for dividend payments. - Overall, the company is strategically investing in operational capacity expansion and market presence to sustain growth.

- The company is confident of delivering over 15% revenue growth and 20% EBITDA growth for the full year 2025, in line with initial guidance. - Nine-month data shows strong momentum with 15% revenue growth and 25% volume growth. - Lab-grown diamonds (LGD) and natural diamonds are key contributors, with LGD jewelry growing by 32% in nine months. - Management expects the lab-grown diamond segment to continue propelling industry growth over the next 3-4 years. - No significant change in product demand mix is expected; jewelry demand for gold, silver, natural diamonds, and LGD is steady and equally strong. - The company plans to capitalize on global market opportunities, leveraging geographic presence in India, US, Netherlands, Dubai, China, etc. - Expansion in international labs and acquisitions remain potential growth avenues but no specific plans disclosed yet.

- The management maintains guidance of over 15% revenue growth and 20% EBITDA growth for the full year 2025, with confidence in meeting or surpassing these targets. - Long-term outlook (3-4 years) remains positive, especially due to the growing lab-grown diamond (LGD) industry, which is seen as propelling overall market growth. - They expect PAT margins to stabilize between 40-45%, consistent with past performance. - Despite some tariff-related uncertainties, no significant disruption is expected, aided by IGI’s global presence enabling supply chain flexibility. - The company continues to invest in scaling up operations and exploring acquisition opportunities, supported by strong cash reserves and profit generation. - Volume and revenue growth trends show sustainable strength, with a 25%-26% volume growth and steady pricing, indicating robust demand and market share gains.

The transcript does not explicitly mention current or expected order book or pending orders for International Gemmological Institute (India) Ltd. However, relevant insights include: - Strong volume growth with 3.45 million reports in Q3 2025, a 26% increase YoY, indicating robust demand. - Revenue growth and operational momentum suggest sustained business activity without any indicated backlog issues. - The management highlights steady demand driven by natural diamonds, lab-grown diamonds, and LGD jewelry segments. - No direct references to pending or backlog orders were made during the call. - They are closely monitoring supply chains and tariff impacts but have not reported any disruption causing pending orders. Overall, the company appears to be operating with strong current demand and capacity utilization, with no explicit mention of order backlog or pending orders.